Context Therapeutics, Inc. CNTX 深 沪
等待开盘 03-28 09:30:00 美东时间
2.595
+0.055
+2.17%
华盛通- 最 高3.62
- 今 开2.52
- 成交量 43.83万股
- 最 低 2.16
- 昨 收 2.54
- 总市值 4.14万
- 52周最高 3.62
- 市盈率 静 --
- 换手率 2744.92%
- 52周最低 0.49
- 委 比 19.00%
- 总股本 1.60万
- 历史最高 10.85
- 量 比 0.86
- 振 幅 57.48%
- 历史最低 0.43
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of GH Research PLC (NASDAQ:GHRS) rose sharply in pre-market trading afte...
01-05 17:27
Concentrix Schedules Release of Second Quarter 2025 Financial Results and Webcast of Investor Conference Call
Concentrix Corporation will announce its Q2 2025 financial results after market close on June 26, 2025, and host a conference call with investors the same evening at 5:00 pm Eastern Time. The call will be available via webcast on its Investor Relations website, with a replay to follow.
2025-06-11 12:00
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Context Therapeutics is presenting a Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager, targeting ovarian, endometrial, and testicular cancers. The trial aims to evaluate safety and efficacy in CLDN6-positive advanced cancers, with up to 70 patients enrolled. The company has dosed Cohort 3 and expects to share initial data in the first half of 2026. The trial is conducted at 7 active sites in the U.S.
2025-06-02 11:30
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Context Therapeutics appoints Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin brings over a decade of experience in T cell therapy development, including leading the approval of Tecelra® at Adaptimmune. She succeeds Dr. Karen Smith, who will remain on the Board.
2025-05-29 11:30
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics will present two studies at the upcoming EULAR 2025 Congress in Barcelona, highlighting their iPSC-derived cell therapies for autoimmune diseases and cancer.
2025-05-28 20:01
HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $6 price target.
2024-09-16 19:37
